Navigation Links
Sensipar® Patents Upheld By District Court
Date:1/7/2011

THOUSAND OAKS, Calif., Jan. 7, 2011 /PRNewswire/ -- A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen's (Nasdaq: AMGN) Sensipar® (cinacalcet) until expiration of the drug's U.S. patents.  The latest Sensipar expiry is in 2018.  Sensipar is approved for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis and for the treatment of elevated levels of calcium in patients with parathyroid carcinoma.

"We are pleased with the Court's ruling, which validates Amgen's position that the Sensipar patents are valid, enforceable and infringed," said David Scott, Amgen's senior vice president, general counsel and secretary. Scott added: "Amgen will continue to vigorously defend its innovative products from infringement."

Three patents were the subject of the injunction: U.S. Patent No. 6,011,068 ("the `068 patent") and U.S. Patent No. 6,031,003 expire Dec.14, 2016, but the `068 patent is the subject of a patent term extension which will extend the term to March 8, 2018.  U.S. Patent No. 6,211,244 expires Oct. 23, 2015.

About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics.  A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.  Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.  With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.  To learn more about our pioneering science and our vital medicines, visit www.amgen.com.CONTACT: Amgen, Thousand OaksDavid Polk, 805-447-4613 (media)Arvind Sood, 805-447-1060 (investors)(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs
2. Interventional Spine®, Inc. Announces Issuance of Key Patents for the PERPOS® PLS System
3. Microfluidic Systems (MFSI) is Awarded Four New Patents in the Field of Automated Biological Sample Processing and Detection.
4. Volcano Corporation Files Counterclaim Asserting St. Jude Infringes Three Volcano Patents; Answers St. Judes Patent Infringement Claims
5. Amedica® Receives Patents for Innovative Motion-Preserving Total Disc Implant Featuring Silicon Nitride
6. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
7. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
8. PDL BioPharma Receives Letter from Genentech Relating to European Patents
9. Olympus America Licenses Digital Pathology Patents to BioImagene, Inc.
10. Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents
11. ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Wells Specialty Pharmacy announces the acquisitions and merger ... Winter Park, Florida and Pharm-EZ Medical, ... have been consolidated into the 3796 Howell Branch Road Facility. ... that Chad Tomlinson , former Vice President of Operations, ... Mr. Tomlinson is a Graduate of Florida State University and ...
(Date:1/19/2017)... 2017 Report Details What can ... are going to grow at the fastest rates? This ... data, trends, opportunities and prospects. Our 190-page report ... lucrative areas in the industry and the future market ... across the all the major categories of the ophthalmic ...
(Date:1/19/2017)... This report on the opioid induced constipation ... the global market. Large number of chronic pain sufferers ... is a major side effect of consumption of opioid ... therapy has been prescribed to treat opioid induced constipation. ... and growing awareness about the therapy are the major ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account ... Word: Chocolate Biscuit” is the creation of published author, Marlyn Ivey, born in Lynn Haven, ... he went to school and at 19 years of age, he joined the Navy and ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study indicating superior ... MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices During ...
(Date:1/20/2017)... ... ... to Christmas:” a beautiful and enchanting tale that teaches children the true meaning of Christmas. ... in Oklahoma City, and a devoted woman of faith. , “Becoming a parent changes ... back of my mind for years, but actually doing it might have been a while ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Land ... brings attention to the issue of world hunger, and shares the simple and achievable ... Brubaker, devoted husband and member of the Fairview Missionary Church in Angola, Indiana where ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for Medicare & Medicaid ... CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid ... important part of the Administration’s effort to build a system that delivers better care ...
Breaking Medicine News(10 mins):